Logo
  • Who We Aredown-arrow
    • About Us
    • Mission & Vision
    • Team Overview
    • Careers
  • What We Offerdown-arrow
    • Our Products
    • Our Pipeline
    • Customers & Partners
    • Case Studies & Whitepapers
  • How We Workdown-arrow
    • Our Approach
    • Quality Assurance
    • Our Technology
    • Security
  • Why Usdown-arrow
    • News & Media
    • Events
    • Articles
    • Blog
    • Testimonials & Awards
    • Newsletter
  • Contact Us

CASE STUDIES & WHITEPAPERS

WHITEPAPER

Autoimmune Innovation Index Second Edition

This report captures the evolving clinical landscape across autoimmune diseases, featuring key global pharma and biotech players working on novel therapeutic modalities to advance these diseases.Download PDF
WHITEPAPER

AUTOIMMUNE INDEX REPORT

Autoimmune Index report provides you with a perspective on the new commercial and clinical opportunities by assessing their clinical innovation aspect. Innoplexus’ AI based CTP engine was leveraged to predict the success probability of clinical assets.Download PDF
WHITEPAPER

INNOPLEXUS’ CTP MODEL

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements.Download PDF
WHITEPAPER

GENE THERAPY

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. By replacing a faulty gene in a patient’s DNA or repairing a defective gene by gene editing, gene therapy can provide a one-time treatment option for diseases such as genetic blindness, muscular dystrophy, blood cancer. Read our recent whitepaper: Advancements in gene therapy – usage of AAV vectors here.Download PDF
speaker-icon
What’s New in Ontosight® Terminal 1 . 1

What’s New in Ontosight® Terminal 1 . 1

Read more
Partex Accelerates Antibody Engineering for Neurodegenerative Diseases Using NVIDIA-Accelerated AI / ML Platform

Partex Accelerates Antibody Engineering for Neurodegenerative Diseases Using NVIDIA-Accelerated AI / ML Platform

Read more
Partex and Ark Biopharmaceutical Expand Strategic Collaboration with New Out-Licensing Agreement for ATR Inhibitor AK0658

Partex and Ark Biopharmaceutical Expand Strategic Collaboration with New Out-Licensing Agreement for ATR Inhibitor AK0658

Read more
award

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
ontosight ad illustration

Ontosight®

FREE for a limited time

Try now

WHO WE ARE

About Us
Mission & Vision
Team Overview
Careers

WHAT WE OFFER

Our Products
Our Pipeline
Customers & Partners
Case Studies & Whitepapers

HOW WE WORK

Our Approach
Quality Assurance
Our Technology
Security

WHY US

News & Media
Events
Articles
Blog
Testimonials
Newsletter

Updates

LinkedInFacebookTwitterYouTube

To get more updates on our products and services, please submit your email address

Frankfurt (Germany)

Innoplexus AG
Frankfurter Strasse 27,
65760 Eschborn

Pune (India)

Innoplexus Consulting Services Pvt. Ltd.
7th Floor, Midas Tower,
Hinjewadi Phase 1 - Pune 57

Iselin (USA)

Innoplexus Holdings, Inc.
33 Wood Avenue South,
Suite 600, Iselin,
NJ 08830

Cham (Switzerland)

Amrit AG
Maschinengasse 12
6330 Cham

Copyright All Rights Reserved © 2025 Innoplexus |Terms of Service |Privacy Policy |Impressum

We use first-party cookies to provide you the best possible experience. Necessary By clicking "Accept", you agree to the use of our cookies on your device.